{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Injection&page=11",
    "query": {
      "condition": "Injection",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 3066,
    "total_pages": 307,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Injection&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Injection&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T09:24:10.359Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03091673",
      "title": "Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Glucagon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xeris Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 31,
      "start_date": "2017-03-27",
      "completion_date": "2017-09-27",
      "has_results": true,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 7,
      "location_summary": "Stanford, California • Aurora, Colorado • New Haven, Connecticut + 4 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03091673"
    },
    {
      "nct_id": "NCT05702983",
      "title": "The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antineutrophil Cytoplasmic Antibody Associated Vasculitis"
      ],
      "interventions": [
        {
          "name": "STSA-1002 subcutaneous injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Staidson (Beijing) Biopharmaceuticals Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "57 Years",
        "sex": "ALL",
        "summary": "21 Years to 57 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-01-31",
      "completion_date": "2023-04-24",
      "has_results": false,
      "last_update_posted_date": "2023-05-26",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05702983"
    },
    {
      "nct_id": "NCT06216886",
      "title": "OnabotulinumtoxinA for Trigeminal Neuralgia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Trigeminal Neuralgia"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA 100 UNT [Botox]",
          "type": "DRUG"
        },
        {
          "name": "Sodium Chloride 0.9% for Injection, Preservative Free",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-06-01",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06216886"
    },
    {
      "nct_id": "NCT04850118",
      "title": "A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "X-Linked Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "rAAV2tYF-GRK1-hRPGRco",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Beacon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "12 Years to 50 Years · Male only"
      },
      "enrollment_count": 85,
      "start_date": "2024-03-14",
      "completion_date": "2031-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04850118"
    },
    {
      "nct_id": "NCT02855983",
      "title": "Perforating Fat Injections for Plantar Fasciosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Plantar Fascia"
      ],
      "interventions": [
        {
          "name": "Fat Grafting",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2016-08",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2020-01-10",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02855983"
    },
    {
      "nct_id": "NCT04101682",
      "title": "Continuous Vs Single Shot Block After ACL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "ACL Injury"
      ],
      "interventions": [
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-09-25",
      "completion_date": "2022-05-17",
      "has_results": false,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 1,
      "location_summary": "Plainview, New York",
      "locations": [
        {
          "city": "Plainview",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04101682"
    },
    {
      "nct_id": "NCT00656903",
      "title": "High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2008-04-07",
      "completion_date": "2014-08-19",
      "has_results": false,
      "last_update_posted_date": "2019-12-04",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00656903"
    },
    {
      "nct_id": "NCT05399888",
      "title": "A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment Due to Alzheimer's Disease",
        "Alzheimer's Disease Dementia"
      ],
      "interventions": [
        {
          "name": "Diranersen",
          "type": "DRUG"
        },
        {
          "name": "Diranersen-matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 416,
      "start_date": "2022-08-24",
      "completion_date": "2028-06-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05399888"
    },
    {
      "nct_id": "NCT01487070",
      "title": "A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PDR"
      ],
      "interventions": [
        {
          "name": "Macugen (Pegaptanib Sodium)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Institute of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 5,
      "start_date": "2011-04",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2011-12-07",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01487070"
    },
    {
      "nct_id": "NCT02504580",
      "title": "Pilot Herniorrhaphy Study for Postoperative Analgesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "HTX-011",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "HTX-002",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine HCI (Marcaine)",
          "type": "DRUG"
        },
        {
          "name": "HTX-011A",
          "type": "DRUG"
        },
        {
          "name": "HTX-011B",
          "type": "DRUG"
        },
        {
          "name": "HTX-009",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Heron Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 463,
      "start_date": "2015-07",
      "completion_date": "2017-04",
      "has_results": true,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-20T09:24:10.359Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Houston, Texas",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02504580"
    }
  ]
}